A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Pegylated-Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 2 or 3 Hepatitis C Virus Infection

Clinical diagnosis of abuse of certain substances within specified timeframes

Known medical condition that could interfere with participation

Active or suspected cancer within the last 5 years

Female who is pregnant, breastfeeding, or expecting to conceive or donate eggs

Male who is planning to impregnate partner or donate sperm

Male with a pregnant female partner

Chronic hepatitis not caused by HCV

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.